Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry

The only severe acute respiratory syndrome (SARS) vaccine currently being tested in clinical trial consists of inactivated severe acute respiratory syndrome-associate coronavirus (SARS-CoV). However, limited information is available about host immune responses induced by the inactivated SARS vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Yuxian, Zhou, Yusen, Siddiqui, Pamela, Jiang, Shibo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2004
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092874/
https://www.ncbi.nlm.nih.gov/pubmed/15530413
http://dx.doi.org/10.1016/j.bbrc.2004.10.052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092874/
https://www.ncbi.nlm.nih.gov/pubmed/15530413
http://dx.doi.org/10.1016/j.bbrc.2004.10.052

Ejemplares similares